Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support ...

So, I single out Yervoy, Opdualag, Opdivo, and Breyanzi from its oncology ... However, thanks to Camzyos's unique mechanism of action and, more importantly, its excellent clinical data, I believe ...

That may not prove to be a good investment, given the news this week that bempeg failed a phase 3 trial in melanoma as a combination therapy with Bristol-Myers Squibb's Opdivo (nivolumab).

Its cancer franchise – headed by flagship immunotherapy Opdivo (nivolumab ... programmes – which are both based on novel mechanisms of action – have been keenly anticipated by physicians ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits.